Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + gemcitabine + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of docetaxel, gemcitabine, and carboplatin is a multi-agent chemotherapy regimen primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) and has been studied in other solid tumors. Docetaxel is a taxane that stabilizes microtubules, inhibiting cell division. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA strands and inhibiting ribonucleotide reductase. Carboplatin is a platinum-based compound that causes DNA crosslinking, leading to apoptosis. Together, these agents act synergistically to disrupt cancer cell proliferation through multiple mechanisms targeting both mitosis and DNA replication[1][4][6][8].
- Other names
- docetaxel and gemcitabine and carboplatin combination chemotherapy
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + gemcitabine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + gemcitabine + carboplatin.